Skip to main content

Table 2 Univariate and multivariable analyses of Disease Free Survival (DFS) and Overall Survival (OS) for the different immune markers and for tumor immune phenotypes

From: Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study

DFS

OS

Univariate analysis

Multivariable analysis**

Univariate analysis

Multivariable analysis**

 

HR

95% CI

p-value

HR

95% CI

p-value

HR

95% CI

p-value

HR

95% CI

p-value

HLA class I

  

0.013*

  

0.548

  

0.075

  

0.984

Loss

1.00

  

1.00

  

1.00

  

1.00

 

Downregulation

0.84

0.58-1.22

 

1.08

0.72-1.62

 

0.78

0.53-1.15

 

1.04

0.68-1.59

Expression

0.64

0.46-0.89

 

0.91

0.63-1.32

 

0.68

0.49-0.95

 

1.03

0.70-1.52

Foxp3+

  

<0.001*

  

0.012*

  

<0.001*

  

0.018*

Below median

1.00

  

1.00

  

1.00

  

1.00

 

Above median

0.62

0.49-0.79

 

0.72

0.56-0.93

 

0.64

0.50-0.81

 

0.73

0.56-0.95

HLA-G

  

0.042*

  

0.849

  

0.056

  

0.418

Weak expression

1.00

  

1.00

  

1.00

  

1.00

 

Strong expression

0.75

0.57-0.99

 

0.85

0.63-1.13

 

0.76

0.58-1.01

 

0.88

0.66-1.19

Immune phenotype

  

<0.001*

  

0.019*

  

<0.001*

  

0.122

Phenotype 1

1.00

  

1.00

  

1.00

  

1.00

 

Phenotype 2

1.26

0.94-1.68

 

1.13

0.83-1.54

 

1.18

0.87-1.58

 

1.07

0.78-1.47

Phenotype 3

2.06

1.54-2.75

 

1.56

1.14-2.14

 

1.88

1.40-2.53

 

1.39

1.01-1.92

TNM stage

  

<0.001*

     

<0.001*

   

I-II

1.00

     

1.00

    

III-IV

2.65

2.09-3.37

    

2.65

2.08-3.38

   

Circumferential margin

  

<0.001*

     

<0.001*

   

Negative

1.00

     

1.00

    

Positive

2.26

1.73-2.94

    

2.42

1.85-3.16

   

Age (continuous)

1.03

1.02-1.04

<0.001*

   

1.04

1.03-1.05

<0.001*

   

Tumor grade

  

0.094

     

0.058

   

Well

1.00

     

1.00

    

Moderate

0.88

0.53-1.46

    

0.87

0.52-1.44

   

Poor

1.19

0.69-2.04

    

1.21

0.70-2.09

   

Adjuvant chemotherapy

  

<0.001*

     

<0.001*

   

No

1.00

     

1.00

    

Yes

2.38

1.77-3.20

    

2.43

1.80-3.28

   
  1. *Statistical significance.
  2. **Corrected for TNM stage, circumferential margin, age, tumor grade and adjuvant therapy.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us